Adjunct Therapy for Sepsis: How Early?
- First Online:
Sepsis is a leading cause of death worldwide. The management of patients is primarily based on curing the infectious process with anti-infective drugs and/or surgical drainage. Simultaneously, treatment includes optimization of oxygen use by tissues via appropriate oxygen therapy and respiratory and hemodynamic management. At best, initiating appropriate anti-infective and symptomatic treatments should lead to patient improvement within a few hours. Activated protein C and hydrocortisone are the only two available adjunct therapies for sepsis. These treatments should optimally be started within 24 hours of the onset of shock. They should be initiated in those patients who did not adequately respond after 6 hours of optimal anti-infective and symptomatic treatments.
KeywordsInfection Inflammation Apoptosis Coagulation Shock Organ dysfunction Hydrocortisone Activated protein C
Papers of particular interest, published recently, have been highlighted as: •Of importance ••Of major importance
- 13.• Marik PE, Pastores SM, Annane D, et al.: Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008, 36:1937–1949. This article provides a comprehensive approach to the rationale and clinical evidence for the use of corticosteroids in critical illness.CrossRefPubMedGoogle Scholar
- 14.•• Annane D, Bellissant E, Bollaert PE, et al.: Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 2009, 301:2362–2375. This systematic review clearly establishes the current evidence favoring the use of corticosteroids in septic shock. In addition, it provides useful information on the practical modalities for using corticosteroids in septic shock.CrossRefPubMedGoogle Scholar
- 15.•• COIITSS Study Investigators, Annane D, Cariou A, Maxime V, et al.: Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 2010, 303:341–348. This is the first multicenter, randomized, controlled trial investigating the benefit-to-risk ratio of normalizing blood glucose levels in corticosteroid-treated patients. The study demonstrated that tight glucose control was not superior to moderate glucose control.CrossRefPubMedGoogle Scholar
- 16.•• Sprung C, Annane D, Keh D, et al.: The CORTICUS randomized, double-blind, placebo-controlled study of hydrocortisone therapy in patients with septic shock. N Engl J Med 2008, 358:111–124. This article challenges the benefit of corticosteroids in septic shock. Although hydrocortisone therapy hastens shock reversal and organ dysfunction resolution, no evidence was shown for survival benefit and there was an apparent increase in superinfections.CrossRefPubMedGoogle Scholar
- 22.Tandan SM, Guleria R, Gupta N: Low dose steroids and adrenocortical insufficiency in septic shock: a double-blind randomised controlled trial from India [abstract]. Proceedings of the American Thoracic Society Meeting. New York: American Thoracic Society; 2005:A24.Google Scholar
- 26.•• Meduri GU, Golden E, Freire AX, et al.: Methylprednisolone infusion in early ARDS: result of a randomised controlled trial. Chest 2007, 131:954–963. This article describes the first multicenter trial of moderate doses of corticosteroids in early ARDS patients. There was strong evidence for morbidity benefits.CrossRefPubMedGoogle Scholar
- 27.Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005, 365:63–78.Google Scholar
- 37.•• Nadel S, Goldstein B, Williams MD, et al.: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836–843. This was the largest trial of activated protein C in children. There was no apparent benefit and an increased risk of serious bleeding.CrossRefPubMedGoogle Scholar
- 38.• Marti-Carvajal A, Salanti G, Cardona A: Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev, 2008:CD004388. This is an important systematic review challenging the benefit-to-risk ratio of activated protein C.Google Scholar
- 39.• Levi M, Levy M, Williams MD, et al.: Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med 2007, 176:483–490. This trial demonstrated no significant interaction between activated protein C and prophylactic heparin.CrossRefPubMedGoogle Scholar